Our review investigates various mechanisms of resistance to BCL2 inhibitors, including mutations in BCL2, alterations in the Bcl protein pathway, epigenetic modifications, genetic …

2020年3月5日 · In this issue of Blood, Blombery and colleagues have identified multiple novel somatic mutations in BCL-2 occurring concurrently with the recently reported Gly101Val BCL-2 …

2021年6月10日 · This article will focus on the treatment approach of CLL patients with BCl2 antagonists. Treatment strategy (combined versus monotherapy; continuous versus limited …

2025年3月3日 · We comprehensively defined BCL-2 dependence as a potential functional and predictive biomarker of treatment response in CLL, underscoring the importance of …

2025年3月3日 · We comprehensively defined BCL-2 dependence as a potential functional and predictive biomarker of treatment response in CLL, underscoring the importance of …

Introduction: In the last decade, BTK inhibitors and the BCL-2 inhibitor venetoclax have replaced immunochemotherapy in the treatment of CLL. Areas covered: This review describes the use …

In this review, we have focused on the role of Bcl-2 family proteins in apoptosis control in CLL. The presence of high levels of Bcl-2 in the majority of patients, and the genetic alterations of …

2024年12月26日 · Venetoclax, a first-in-class BH3 mimetic drug that targets B-cell lymphoma-2 (BCL-2), has improved the outcomes of patients with chronic lymphocytic leukemia (CLL). …

5 天之前 · The following is a summary of "BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia," published in the March 2025 issue of …

2024年10月6日 · This review describes the use of BTK inhibitors and BCL2 inhibitors in the treatment of naive and relapsed or refractory CLL, with particular attention to the mechanisms …